Baudax Bio, Inc.
BXRX · NASDAQ
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $30 | -$14 | $310 |
| % Growth | -100% | 314.3% | -104.5% | – |
| Cost of Goods Sold | $43 | $104 | $405 | $4,792 |
| Gross Profit | -$43 | -$74 | -$419 | -$4,482 |
| % Margin | – | -246.7% | 2,992.9% | -1,445.8% |
| R&D Expenses | $1,901 | $1,779 | $2,917 | $1,038 |
| G&A Expenses | $3,639 | $2,254 | $0 | $0 |
| SG&A Expenses | $3,639 | $2,254 | $1,771 | $2,092 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$256 | -$2,698 | $65 |
| Operating Expenses | $5,540 | $4,033 | $4,688 | $3,195 |
| Operating Income | -$1,776 | -$7,045 | -$4,688 | -$8,600 |
| % Margin | – | -23,483.3% | 33,485.7% | -2,774.2% |
| Other Income/Exp. Net | $0 | -$3,268 | -$2,698 | -$1,574 |
| Pre-Tax Income | -$1,776 | -$7,301 | -$7,386 | -$9,249 |
| Tax Expense | $158 | $3,086 | $206 | $0 |
| Net Income | -$1,934 | -$7,375 | $11,404 | -$9,249 |
| % Margin | – | -24,583.3% | -81,457.1% | -2,983.5% |
| EPS | -0.24 | -1.51 | 4.91 | -5.7 |
| % Growth | 84.1% | -130.8% | 186.1% | – |
| EPS Diluted | -0.24 | -1.51 | 4.91 | -5.7 |
| Weighted Avg Shares Out | 7,994 | 4,885 | 2,319 | 1,624 |
| Weighted Avg Shares Out Dil | 7,994 | 4,885 | 2,323 | 1,624 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $921 |
| Depreciation & Amortization | $131 | $1 | $3 | $1,911 |
| EBITDA | -$43 | -$74 | -$23,681 | -$6,689 |
| % Margin | – | -246.7% | 169,150% | -2,157.7% |